100 466

Cited 11 times in

Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.

DC Field Value Language
dc.contributor.authorPark, SH-
dc.contributor.authorKim, CH-
dc.contributor.authorKim, DJ-
dc.contributor.authorSuk, KT-
dc.contributor.authorPark, JH-
dc.contributor.authorCheong, JY-
dc.contributor.authorCho, SW-
dc.contributor.authorHwang, SG-
dc.contributor.authorLee, YJ-
dc.contributor.authorCho, M-
dc.contributor.authorYang, JM-
dc.contributor.authorPark, HY-
dc.contributor.authorKim, YB-
dc.date.accessioned2012-04-20-
dc.date.available2012-04-20-
dc.date.issued2011-
dc.identifier.issn0009-9120-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/6446-
dc.description.abstractOBJECTIVES: Whether new biomarkers contribute significantly to the existing, simple noninvasive test (comprising of routine laboratory parameters such as the AST to platelet ratio index (APRI)) for predicting liver fibrosis remains unknown.



METHODS: We measured 7 biomarkers in 91 patients with chronic hepatitis C (CHC): haptoglobin, apolipoprotein A1, α2-macroglobulin, hyaluronic acid, type III procollagenic peptide, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1.



RESULTS: The "multibiomarker" score (based on regression coefficients of significant biomarkers) is an independent predictive factor for significant fibrosis [APRI-adjusted odds ratio, 2.41 (95% CI, 1.28 to 4.55)]. However, the incorporation of the multibiomarker score into the APRI resulted in only a small diagnostic improvement [0.83 (95% CI, 0.74 to 0.92) vs. 0.79 (0.69 to 0.89); p=0.19].



CONCLUSIONS: For assessing significant fibrosis in individual CHC patients, the 7 contemporary biomarkers that we studied add only modestly to the readily available, simple noninvasive index.
-
dc.language.isoen-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHApolipoprotein A-I/blood-
dc.subject.MESHAspartate Aminotransferases/blood-
dc.subject.MESHBiological Markers/blood-
dc.subject.MESHCollagen Type III/blood-
dc.subject.MESHFemale-
dc.subject.MESHHaptoglobins/metabolism-
dc.subject.MESHHepatitis C, Chronic/blood/*complications-
dc.subject.MESHHumans-
dc.subject.MESHHyaluronic Acid/*blood-
dc.subject.MESHLiver Cirrhosis/blood/*diagnosis/etiology-
dc.subject.MESHMale-
dc.subject.MESHMatrix Metalloproteinase 2/blood-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHROC Curve-
dc.subject.MESHTissue Inhibitor of Metalloproteinase-1/blood-
dc.subject.MESHYoung Adult-
dc.subject.MESHalpha-Macroglobulins/*metabolism-
dc.titleDiagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.-
dc.typeArticle-
dc.identifier.pmid21971609-
dc.identifier.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0009-9120(11)02650-6-
dc.contributor.affiliatedAuthor정, 재연-
dc.contributor.affiliatedAuthor조, 성원-
dc.contributor.affiliatedAuthor김, 영배-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.clinbiochem.2011.08.1151-
dc.citation.titleClinical biochemistry-
dc.citation.volume44-
dc.citation.number17-18-
dc.citation.date2011-
dc.citation.startPage1396-
dc.citation.endPage1399-
dc.identifier.bibliographicCitationClinical biochemistry, 44(17-18):1396-1399, 2011-
dc.identifier.eissn1873-2933-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
21971609.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse